Survival in human colorectal cancer correlates with expression of the T-cell costimulatory molecule OX-40 (CD134)

American Journal of Surgery

Volumn 183, Issue 5, 2002, Pages 512-518

  Petty, John K ^a   He, Ken ^a   Corless, Christopher L ^a   Vetto, John T ^a   Weinberg, Andrew D ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PROVIDENCE PORTLAND MEDICAL CENTER   (United States)

Author keywords

Colorectal cancer; Human; Immunotherapy; OX 40 (CD134); T cell

Indexed keywords

CD134 ANTIGEN;

ADULT; AGED; CANCER REGISTRY; CANCER SURVIVAL; COLORECTAL CANCER; CONFERENCE PAPER; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; MESENTERY LYMPH NODE; METASTASIS; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD27; ANTIGENS, NEOPLASM; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROGNOSIS; RECEPTORS, IMMUNOLOGIC; RECEPTORS, OX40; RECEPTORS, TUMOR NECROSIS FACTOR; SURVIVAL ANALYSIS;

EID: 0036273628     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9610(02)00831-0     Document Type: Conference Paper

References (34)

1. T cell-based immunotherapy for cancer: A virtual reality?
2. Cancer statistics 2000
3. A new prognostic classification of rectal cancer
4. Identification of colon-tumor-associated antigens by T cell lines derived from tumor-infiltrating lymphocytes and peripheral-blood lymphocytes from patients immunized with an autologous tumor-cell/bacillus calmette-guerin vaccine
5. Histocompatibility leukocyte antigen-A2402-restricted cytotoxic T lymphocytes of patients with colon cancer
6. Culture of tumor-infiltrating lymphocytes from melanoma and colon carcinoma: Removal of tumor cells does not affect tumor-specificity
7. Localization of tumor-reactive lymph node lymphocytes in vivo using radiolabeled monoclonal antibody
8. Expression of class II major histocompatibility complex molecules correlates with human colon tumor vaccine efficacy
9. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma
10. Purification of L-selectin low cells promotes the generation of highly potent CD4 antitumor effector T lymphocytes
11. Antigens of activated rat T lymphocytes including a molecule of 50,000 Mr detected only on CD4 positive T blasts
12. The tumor necrosis ligand and receptor families
13. OX-40: Life beyond the effector T cell stage
14. Cloning of mouse OX-40: A T cell activation marker that may mediate T-B interactions
15. Crosslinking of OX-40 ligand, a member of the TNF/NGF cytokine family, induces proliferation and differentiation in murine splenic cells
16. Expression and function of OX-40 ligand on human dendritic cells
17. The human OX-40/gp34 system directly mediates adhesion of activated T cells to vascular endothelial cells
18. Danger and OX-40 receptor signalling synergize to enhance memory T cell survival by inhibiting peripheral deletion
19. + T cell mobilization/memory development and humoral immunity: Comparison of OX-40 with alpha CTLA-4
20. Engagement of the OX-40 receptor in vivo enhances antitumor immunity
21. Presence of the T cell activation marker OX-40 on tumor infiltrating lymphocytes and draining lymph node cells from patients with melanoma and head and neck cancers
22. Immunohistochemical analysis of primary breast tumors and tumor-draining lymph nodes by means of the T cell costimulatory molecule OX-40
23. Antibodies to OX-40 (CD134) can identify and eliminate autoreactive T cells: Implications for human autoimmune disease
24. Target organ specific upregulation of the MRC OX-40 marker and selective production of Th1 lymphokine mRNA by encephalitogenic T helper cells isolated from the spinal cord of rats with experimental autoimmune encephalomyelits
25. Selective depletion of myelin-reactive T cells with the anti-OX-40 antibody ameliorates autoimmune encephalomyelitis
26. Characterization of activated lymphocytes in colon cancer
27. Human colorectal tumour infiltrating lymphocytes express activation markers and the CD45RO molecule, showing a primed population of lymphocytes in the tumor area
28. Expression of costimulatory molecules B7.1 and B7.2 by macrophages along invasive margin of colon cancer: A possible antitumor immunity?
29. The cytokine microenvironment of human colon carcinoma
30. Human colon cancer cells express the functional Fas ligand
31. A modification of the JAM test is necessary for a correct determination of apoptosis induced by FasL+ adherent tumor cells
32. Differential expression of HLA-DR, HLA-DP, HLA-DQ, and associated invariant chain (Ii) in normal colorectal mucosa, adenoma, and carcinoma
33. Expression of MHC class I and class II antigens in colonic carcinomas
34. Assessment of invasive growth pattern and lymphocytic infiltration in colorectal cancer